<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03528434</url>
  </required_header>
  <id_info>
    <org_study_id>1712339562</org_study_id>
    <nct_id>NCT03528434</nct_id>
  </id_info>
  <brief_title>Zinc for Infection Prevention in Sickle Cell Anemia (ZIPS)</brief_title>
  <acronym>ZIPS</acronym>
  <official_title>for Infection Prevention in Sickle Cell Anemia (ZIPS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Makerere University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jinja Regional Referral Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Université de Montréal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized double-blinded placebo-controlled trial of zinc to reduce the incidence of
      severe or invasive infections in Ugandan children with sickle cell anemia (SCA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be a randomized, placebo-controlled, double blind clinical trial in which 250
      Ugandan children 1.00-4.99 years of age with SCA will receive zinc (10 mg oral dispersible
      tablet daily) or placebo (identical to zinc in appearance) for 12 months. The primary study
      outcome will be incidence of severe or invasive infections. Secondary outcomes will include
      incidence of all clinical infections, confirmed bacterial infections (by culture or PCR),
      incidence of vaso-occlusive crisis (VOC), change in height-for-age z-score, and incidence of
      zinc-related adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomized, placebo-controlled, double blind clinical trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of infection</measure>
    <time_frame>12 months</time_frame>
    <description>The investigators will assess reduction in incidence of severe or invasive infections, with or without culture or PCR confirmation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of all clinical infections</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of all clinical infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of confirmed bacterial infections (by culture or PCR)</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of confirmed bacterial infections (by culture or PCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of vaso-occlusive crisis (VOC)</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of vaso-occlusive crisis (VOC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in height-for-age z-score</measure>
    <time_frame>Enrollment to 12 months</time_frame>
    <description>Change in height-for-age z-score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of zinc-related adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of zinc-related adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Zinc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dietary Supplement: Zinc 10mg dispersible zinc sulfate tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dispersible tablet with inert ingredients, identical to zinc in appearance</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Zinc</intervention_name>
    <description>10mg dispersible zinc sulfate tablet</description>
    <arm_group_label>Zinc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dispersible tablet with inert ingredients, identical to zinc in appearance</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Documented sickle cell anemia (HbSS supported by hemoglobin electrophoresis)

          2. Age range of 1.00-4.99 years, inclusive, at the time of enrollment

          3. Weight at least 5.0 kg at the time of enrollment

          4. Willingness to comply with all study-related treatments, evaluations, and follow-up

        Exclusion Criteria:

          1. Known other chronic medical condition (e.g., HIV, malignancy, active clinical
             tuberculosis)

          2. Severe malnutrition determined by impaired growth parameters as defined by WHO (weight
             for length/height or height for age z-score &lt;-3, using WHO growth standards)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chandy C. John, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carrie Nijak, RN</last_name>
    <phone>+1 317 274 8804</phone>
    <email>cnijak@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ruth Namazzi, MBChB</last_name>
    <phone>+256 772 356 331</phone>
    <email>namazzi101@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jinja Reginal Referral Hospital</name>
      <address>
        <city>Jinja</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Opoka, MD</last_name>
      <phone>+256 772996164</phone>
      <email>opokabob@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2018</study_first_submitted>
  <study_first_submitted_qc>May 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2018</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Chandy John</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Zinc</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zinc</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

